sci論文寫作要點及選刊和投稿注意事項心血管照日格圖(編輯修改稿)
2025-08-13 17:02 本頁面
【文章內(nèi)容簡介】 tes, with a chosen margin of noninferiority of 10 percentage points. 14 cases of LAM including one autopsy were collected from XXX hospital. Data of 14 cases with LAM including one autopsy were collected from XXX hospital. There were 19 men and 6 women of the 25 cases with age range from 24 to 76 years (mean age, years). Of the 25 cases, 19 were men and 6 were women with age ranged from 24 to 76 (mean ) years. 結(jié) 果 Results 介紹最主要的研究結(jié)果 ， 主要終點指標 。 時態(tài)用一般過去時 。 應(yīng)介紹一些關(guān)鍵的數(shù)字 ， 包括統(tǒng)計學(xué)處理結(jié)果 （ 具有可信區(qū)間的有關(guān)數(shù)據(jù)或 P值等 ） 。 在摘要的結(jié)果部分描述結(jié)果時 ， 應(yīng)當(dāng)避免的一些情況： The results of our study showed that … It was shown that … The present study showed that … 等等 。 因為前面有個小標題 Results， 可以直接開始描述結(jié)果 。 下面是 N Engl J Med一篇摘要的結(jié)果部分： Results The mortality rate was percent in the placebo group and percent in the drotrecogin alfa activated group. On the basis of the prospectively defined primary analysis, treatment with drotrecogin alfa activated was associated with a reduction in the relative risk of death of percent (95 percent confidence interval, to ) and an absolute reduction in the risk of death of percent (P=). The incidence of serious bleeding was higher in the drotrecogin alfa activated group than in the placebo group ( percent vs. percent, P=). (初步修改 ) ③ The positive rates of B19DNA and IgM in patients with SchonleinHenoch purpura, juvenile rheumatoid arthritis, dermatomyositis, systemic lupus erythematosus and Kawasaki disease were 25% and 20%, % and 20%, 40% and 20%, % and %, % and %, respectively. There was no significant difference in the positive rates of B19DNA and IgM among the above five types of children39。s mon rheumatism disorders of children (P). (進一步修改 ) ③ No significant differences in positivity rates of B19DNA and IgM antibody were found among the patients with SchonleinHenoch purpura, juvenile rheumatoid arthritis, dermatomyositis, systemic lupus erythematosus and Kawasaki disease (P). RESULTS—Of 900 patients receiving LM75/25 and 918 patients receiving glargine who pleted initiation, 473 and 419, respectively, had A1C % and continued into maintenance. Baseline characteristics except age were similar in this group. Median time of maintaining the A1C goal was months for LM75/25 (95%CI –) and months for glargine (95% CI –。 P = ). A1C goal was maintained in 202 LM75/25treated patients (43%) and in 147 glarginetreated patients
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1